Teoxane SA - Jan 6, 2025 Form SCHEDULE 13D/A Schedule Report for Revance Therapeutics, Inc. (RVNC)

Filing Manager: Teoxane SA
Reporting Manager: Teoxane SA
Security: Revance Therapeutics, Inc. Common Stock, par value $0.001 per share
Symbol: RVNC
Shares outstanding: 106M shares
Disclosed Ownership: 6.55M shares
Ownership: 6.2%
Form type: SCHEDULE 13D/A
Date filed: 1/6/2025, 09:00 AM
Date of event: Jan 6, 2025
Previous filing: Dec 19, 2024
Next filing: Jan 30, 2025
SEC: View on sec.gov

Reporting Managers (1)

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title	CIK
Teoxane SA	6.2%	6.55M	6.55M	0	/s/ Patrice Calvayrac	Patrice Calvayrac/ Chief Financial Officer	0001992112